PATRICK DEVAL L - 01 Nov 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Nov 2023
Net transactions value
-$373,009
Form type
4
Filing time
03 Nov 2023, 16:15:10 UTC
Previous filing
19 Sep 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $380,241 +30,130 +918% $12.62 33,412 01 Nov 2023 Direct F1, F2
transaction CERE Common Stock Sale $753,250 -30,130 -90% $25.00 3,282 01 Nov 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -30,130 -71% $0.000000 12,555 01 Nov 2023 Common Stock 30,130 $12.62 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person.
F2 Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan that were previously reported by the Reporting Person.
F3 This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021.